Ameriprise’s Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A BSX.PRA Stock Holding History

Ameriprise’s Portfolio BSX.PRA Stock Details BSX.PRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-461,500	Closed	-$55.6M	–	4044
2023 Q1	$55.6M	Sell	461,500 -65,550	-12%	-$7.54M	0.02%	700
2022 Q4	$60.5M	Sell	527,050 -50,000	-9%	-$5.51M	0.02%	654
2022 Q3	$59.5M	Hold	577,050	–	–	0.02%	632
2022 Q2	$58.6M	Buy	577,050 +259,800	+82%	+$28.3M	0.02%	660
2022 Q1	$37.5M	Sell	317,250 -25,000	-7%	-$2.89M	0.01%	934
2021 Q4	$39.3M	Buy	+342,250	New	+$39M	0.01%	959
2020 Q4	–	Sell	-485,700	Closed	-$54.3M	–	3844
2020 Q3	$54.3M	Buy	485,700 +97,400	+25%	+$10.9M	0.02%	603
2020 Q2	$40.6M	Buy	+388,300	New	+$41.6M	0.02%	695

Other funds holding BSX.PRA

LTI

Laffer Tengler Investments Nashville, Tennessee $782M AUM 33.6% 1-Year Est. Return

Ameriprise's BSX.PRA Position: Q2 2023 in Review

Ameriprise sold out of Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A (BSX.PRA) in Q2 2023, closing a stake of 461,500 shares — an estimated $55.6M sold.

Ameriprise first reported a position in BSX.PRA in Q2 2020 and held it in 8 quarters. The position peaked at $60.5M in Q4 2022. 1 fund tracked by Wall St. Rank holds BSX.PRA as of Q2 2023.

Ameriprise reported no remaining Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A position as of Q2 2023 after selling out during the quarter.
Ameriprise sold 461,500 Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A shares in Q2 2023, an estimated $55.6M.
Ameriprise first reported a position in Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A in Q2 2020 and held it in 8 quarters.
Ameriprise's Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A position peaked at $60.5M in Q4 2022.
1 fund tracked by Wall St. Rank held Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A as of Q2 2023.

Based on Ameriprise's 13F filing for Q2 2023, filed 14 Aug 2023.